SavedAdd your journal

Journals / Adıyaman Üniversitesi Sağlık Bilimleri Dergisi / 2025 / Cilt: 11 Sayı: 3

Two types of luminal B breast cancer: Clinical differences between HER2-negative and HER2-positive metastatic luminal B breast cancer

İki tip luminal B meme kanseri: HER-2 negatif ve HER-2 pozitif metastatik luminal B meme kanseri arasındaki klinik farklılıklar

Mehmet Uzun(Kahramanmaraş Necip Fazıl Şehir Hastanesi)0000-0002-8596-4233
Savaş Gökçek(Kahramanmaraş Necip Fazıl Şehir Hastanesi)0000-0001-5928-0447
Mehmet Meriç Çoban(İzmir Şehir Hastanesi)0000-0001-6823-8080
Eda Çalışkan Yıldırım(Sincan Eğitim ve Araştırma Hastanesi)0000-0003-0785-0238
Elif Atağ(DOKUZ EYLÜL ÜNİVERSİTESİ)0000-0002-2803-9287
Pages
231–240
Publication Date
2025-12-31
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Median overall survival was 29.66 months in the HER-2 positive group and 42.53 months in the HER-2 negative group (p=0.082).

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: To compare clinicopathological features, treatment responses, and survival outcomes of HER-2 positive and HER-2 negative metastatic Luminal B breast cancer.
📊
Key Findings & Data:Materials and Methods: Retrospective data of 130 patients diagnosed between 2010 and 2024 were analyzed.
💡
Conclusion & Impact:Median overall survival was 29.66 months in the HER-2 positive group and 42.53 months in the HER-2 negative group (p=0.082).
🔬Design:Araştırma Makalesi
📍Scope:2010 Verileri
⚙️Variables:Luminal B · HER-2 pozitif · HER-2 negatif

Abstract

Aim: To compare clinicopathological features, treatment responses, and survival outcomes of HER-2 positive and HER-2 negative metastatic Luminal B breast cancer. Materials and Methods: Retrospective data of 130 patients diagnosed between 2010 and 2024 were analyzed. Patients were grouped by HER-2 status, and comparisons were made. Survival analyses used Kaplan-Meier curves, log-rank tests, and Cox regression. Results: Significant differences were observed in ECOG performance status (p<0.001), ER (p=0.001), PR (p=0.046), first-line metastatic treatment (p<0.001), and mortality (p=0.019). Median overall survival was 29.66 months in the HER-2 positive group and 42.53 months in the HER-2 negative group (p=0.082). Conclusion: While survival outcomes did not differ significantly between groups, distinct differences in treatment strategies were identified.

Özet

Amaç: Bu çalışma, HER-2 pozitif ve HER-2 negatif metastatik Luminal B meme kanseri alt tiplerini klinikopatolojik özellikler, tedavi yanıtları ve sağkalım süreleri açısından karşılaştırmayı amaçlamaktadır. Gereç ve Yöntem: 2010-2024 yılları arasında tanı konulan 130 metastatik Luminal B meme kanseri hastasının retrospektif verileri incelendi. Hastalar HER-2 durumuna göre iki gruba ayrıldı; sağkalım Kaplan-Meier, log-rank testi ve Cox regresyon analiziyle değerlendirildi. Bulgular: ECOG (p<0,001), ER (p=0,001), PR (p=0,046), metastatik 1. sıra tedavi (p<0,001) ve mortalite (p=0,019) değişkenlerinde gruplar arasında anlamlı fark bulundu. Median genel sağkalım HER-2 pozitif grupta 29,66 ay, HER-2 negatif grupta 42,53 ay idi (p=0,082). Sonuç: HER-2 durumuna göre sağkalım farklılıkları istatistiksel anlam taşımamakla birlikte, tedavi yaklaşımları arasında belirgin klinik ayrışmalar saptanmıştır.

🔖

Cite This Article

Uzun, M., Gökçek, S., Çoban, M. M., Yıldırım, E. Ç., Atağ, E. (2025). Two types of luminal B breast cancer: Clinical differences between HER2-negative and HER2-positive metastatic luminal B breast cancer. Adıyaman Üniversitesi Sağlık Bilimleri Dergisi, Cilt: 11 Sayı: 3, 231–240. https://doi.org/10.30569/adiyamansaglik.1659044

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (21)

  1. Bizuayehu HM, Dadi AF, Hassen TA, Ketema DB, Ahmed KY, Kassa ZY, et al. Global burden of 34 cancers among women in 2020 and projections to 2040: Population-based data from 185 countries/territories. Int J Cancer. 2024;154(8):1377-1393. doi: 10.1002/ijc.34809.
  2. Zaha DC, Lazăr E, Lăzureanu C. Clinicopathologic features and five years survival analysis in molecular subtypes of breast cancer. Rom J Morphol Embryol. 2010;51(1):85-89.
  3. Li ZH, Hu PH, Tu JH, Yu NS. Luminal B breast cancer: patterns of recurrence and clinical outcome. Oncotarget. 2016;7(40):65024-65033. doi:10.18632/oncotarget.11344
  4. Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-Kains B, et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res. 2008;10(4):R65. doi: 10.1186/bcr2124.
  5. Harbeck N, Thomssen C, Gnant M. St. Gallen 2013: brief preliminary summary of the consensus discussion. Breast Care (Basel). 2013;8(2):102-109. doi:10.1159/000351193
  6. Lee JS, Kim JS, Lee JH, Lee JW, Lee J, Park HY, et al Prepectoral breast reconstruction with complete implant coverage using double-crossed a cellular dermal matrixs. Gland Surg. 2019;8(6):748-757. doi: 10.21037/gs.2019.12.10.
  7. Loibl S, Metzger O, Mandrekar SJ, Mundhenke C, Seiler S, Valagussa P et al. PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + Anti-HER2 therapy + endocrinetherapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer (MBC). Annals of oncology: official journal of the European Society for Medical Oncology. 2018;29:viii121. doi: 10.1093/annonc/mdy272.357
  8. Metzger-Filho O, Sun Z, Viale G, Price KN, Crivellari D, Snyder RD, et al Patterns of Recurrence and outcome according to breast cancer subtypes in lymphnode-negative disease: results from international breast cancer study group trials VIII and IX. J Clin Oncol. 2013;31(25):3083-90. doi: 10.1200/JCO.2012.46.1574.
  9. Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, et al. Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. J Clin Oncol. 2020;38(12):1346-1366. doi: 10.1200/JCO.19.02309.
  10. Irigoyen MA, García FV, Iturriagagoitia AC, Beroiz BI, Martínez MS, GuillénGrima F. Subtipos moleculares del cáncer de mama: implicaciones pronósticas y características clínicas e inmunohistoquímicas [Molecular subtypes of breast cancer: prognostic implications and clinical and immunohistochemical characteristics]. An Sist Sanit Navar. 2011;34(2):219-233. doi:10.4321/s1137-66272011000200008
  11. Prat A, Pineda E, Adamo B, Galván P, Fernández A, Gaba L, et al. Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast. 2015;24 Suppl 2:S26-35. doi: 10.1016/j.breast.2015.07.008.
  12. Prat A, Cheang MC, Martín M, Parker JS, Carrasco E, Caballero R, et al. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol. 2013;31(2):203-9. doi: 10.1200/JCO.2012.43.4134.
  13. Kang B, Lee J, Jung JH, Kim WW, Keum H, Park HY. Differences in clinical outcomes between HER2-negative and HER2-positive luminal B breast cancer. Medicine (Baltimore). 2023;102(34):e34772. doi:10.1097/MD.0000000000034772
  14. Kim EK, Noh WC, Han W, Noh DY. Prognostic significance of young age (<35 years) by subtype based on ER, PR, and HER2 status in breast cancer: a nation wide registry-based study. World J Surg. 2011;35(6):1244-53. doi: 10.1007/s00268-011-1071-1.
  15. Bergen ES, Tichy C, Berghoff AS, Rudas M, Dubsky P, Bago-Horvath Z, et al. Prognostic impact of breast cancer subtypes in elderly patients. Breast Cancer Res Treat. 2016;157(1):91-9. doi: 10.1007/s10549-016-3787-y.
  16. Beith J, Burslem K, Bell R, Woodward N, McCarthy N, De Boer R, et al. Hormone receptor positive, HER2 negative metastatic breast cancer: A systematic review of the current treatment landscape. Asia Pac J Clin Oncol. 2016;12 Suppl 1:3-18. doi: 10.1111/ajco.12491.
  17. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, et al. Panel members. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013;24(9):2206-23. doi: 10.1093/annonc/mdt303.
  18. Lindman H, Wiklund F, Andersen KK. Long-term treatment patterns and survival in metastatic breast cancer by intrinsic subtypes - an observational cohort study in Sweden. BMC Cancer. 2022;22(1):1006. 2022. doi:10.1186/s12885-022-10098-1
  19. Li Y, Wang S, Yang W, Liu H. Prognostic significance of molecular subtype, metastatic site and primary tumor surgery for survival in primary metastatic breast cancer: A SEER-based study. Medicine (Baltimore). 2021;100(27):e26619. doi:10.1097/MD.0000000000026619
  20. Han Y, Wu Y, Xu H, Wang J, Xu B. The impact of hormone receptor on the clinical out comes of HER2-positive breast cancer: a population-based study. Int J Clin Oncol. 2022;27(4):707-716. doi:10.1007/s10147-022-02115-x
  21. Marczyk VR, Rosa DD, Maia AL, Goemann IM. Overall Survival for HER2-Positive Breast Cancer Patients in the HER2-Targeted Era: Evidence From a Population-Based Study. Clin Breast Cancer. 2022;22(5):418-423. doi: 10.1016/j.clbc.2022.03.004.